David P. Luci - 20 Apr 2026 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Reporting relationship: President and CEO, Director
Issuer ticker: ACXP
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 16:17:53 UTC
Prior SEC filing: 06 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci

Key filing fact

David P. Luci filed Form 4 for Acurx Pharmaceuticals, Inc. (ACXP) on 22 Apr 2026.

Key facts

This page summarizes David P. Luci's Form 4 filing for Acurx Pharmaceuticals, Inc. (ACXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Apr 2026, 16:17.

Change

Previous filing in this sequence was filed on 06 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001271123 Primary reporting owner

LUCI DAVID P

Relationship: President and CEO, Director
Address: C/O ACURX PHARMACEUTICALS, INC.,, 259 LIBERTY AVENUE, STATEN ISLAND
Signature: /s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci
Signature date: 22 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACXP transaction Derivative

Stock Option

Award

Transaction value
Shares: +37,100
Change %
Price: $0.000000^*
Shares after: 37,100
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,100
Exercise price: $2.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.